Core Viewpoint - The humanoid robot industry is currently in a technology validation phase, but the timeline for commercialization is expected to be shorter than that of the electric vehicle industry. The focus should be on segments with high value, clear structure, and high certainty, as these will have the greatest performance elasticity [1][22]. Industry Comparison - The humanoid robot industry is highly comparable to the electric vehicle industry, both being global strategic industries initiated by Tesla. They follow similar development patterns driven by technology validation, capital support, and policy incentives, although the complexity and fragmentation of robot intelligence present unique challenges [2][3]. Key Segments - High-value and high-barrier segments in the humanoid robot industry include platform companies (integrating hardware and software), high-performance SOC chips (driving the brain side), dexterous hands (integrated hardware and software small robots), actuators, and precision sensors [1][19][22]. Investment Strategy - The investment strategy should focus on identifying leading companies in the humanoid robot sector that have high non-standard, technical, cost, and production expansion barriers, as these companies are likely to navigate through industry cycles successfully [1][22]. Market Dynamics - The humanoid robot industry is expected to experience a more stable performance trajectory compared to the electric vehicle industry, which has faced significant volatility due to cyclical material performance. The industry is still in its early stages, with no dominant players yet emerging like CATL in the lithium battery sector [19][22]. Policy and Capital Support - Policy and capital support are crucial for the development of both the electric vehicle and humanoid robot industries. The approach for robots should follow a "plan first, market later" strategy, similar to the early days of electric vehicles [5][6].

Core Viewpoint - Recent demand for inference and training computing power is strong, leading to price increases from both Amazon Web Services (AWS) and Google Cloud [1][2] Group 1: Demand for Computing Power - The demand for computing resources for inference and training has significantly increased, supporting the need for training computing power [1] - AWS raised prices by approximately 15% for EC2 machine learning capacity blocks on January 23, 2026, followed by Google Cloud announcing price hikes for its cloud network transmission services, with North America seeing a doubling of prices [2] Group 2: Inference Side - The rapid emergence of AI agents, such as MoltBot, is expected to support the demand for inference computing power, as these agents can perform more complex tasks and require more computing resources [3] - Anthropic has raised its revenue expectations for 2026 and 2027 to $18 billion and $55 billion, respectively, indicating a strong upward trend in inference demand [3] Group 3: Training Side - The industrial sector is continuously exploring scaling limits, which supports the demand for training computing power, with new models expected to be released in Q1 2026 [8] - Models like Grok-5 and GPT-6 are anticipated to utilize larger datasets and parameter scales, increasing the demand for training computing power [8] Group 4: Financial Reporting Catalyst - The upcoming earnings reports from major cloud service providers (CSPs) will be critical in confirming the demand for computing power and capital expenditure continuity [9] - Key earnings dates include Microsoft and Meta on January 29, 2026, followed by Google on February 5 and Amazon on February 6, with NVIDIA's report on February 26 expected to further influence market sentiment [9][10]

Core Viewpoint - The revised Implementation Regulations of the Drug Administration Law of the People's Republic of China have been officially released, emphasizing a legal framework for drug activities that prioritizes public welfare and innovation [1] Industry Summary - The new regulations serve as a tool to refine and implement the Drug Administration Law, indicating a shift towards high-quality development in the pharmaceutical industry, driven by innovation and compliance [1] - The pharmaceutical industry is expected to maintain an overweight position, with investment strategies focusing on three main lines for 2026: 1. Innovation-driven and internationalization, highlighting the importance of companies that focus on innovation and international expansion in a domestic policy environment that discourages excessive competition [1] 2. Self-sufficiency, with an emphasis on core components, reagents, and upstream research that can replace imports, especially in light of potential geopolitical risks [1] 3. New policies and new opportunities, benefiting from optimized centralized procurement, three-payment systems in medical insurance, consumption stimulus policies, and state-owned enterprise reforms [1]

中信证券研报表示，目前人形机器人处于技术验证期，但商业化落地时间相比于新能源汽车将缩短；建 议重点关注机器人产业中价值最厚、格局最清、确定性最高环节，因为业绩弹性最大，同时我们认为龙 头在产业趋势投资阶段最为核心，因此我们建议积极寻找机器人细分环节中非标、技术、成本、扩产壁 垒高的龙头企业，因为这类企业能够穿越产业周期。整体上，我们认为机器人公司本身（软硬一体的平 台型企业）、高算力SOC芯片（大脑端侧驱动）、灵巧手（软硬件一体的小机器人）、执行器、精密传 感器（软硬件一体）等环节属于人形机器人产业高价值、高壁垒环节。 ...

中信证券研报表示，修订后的《中华人民共和国药品管理法实施条例》正式发布。《条例》是细化和落 实《药品管理法》的抓手，展现出我国药品活动的法律法规以民生和创新为导向。我们对照了修订后的 《条例》与2002版《条例》，认为医药行业将以创新为核、合规为基，走向高质量发展。延续2026年的 产业投资策略观点：我们认为医药行业将是有望维持超配的行业，从横向维度上，建议2026年围绕以下 几条主线进行布局：1）创新驱动和国际化—在反内卷的国内政策环境下，关注创新驱动和国际化出海 的相关标的；2）自主可控—我们预计未来可能还会陆续面临地缘政治扰动带来的风险，应更多关注自 主可控下核心零部件、试剂、科研上游的进口替代进程加速的相关标的；3）新政新气象—受益于集采 优化、医保三个支付、消费刺激政策和国企改革的相关标的。 （文章来源：第一财经） ...

（文章来源：第一财经） 中信证券研报表示，目前人形机器人处于技术验证期，但商业化落地时间相比于新能源汽车将缩短；建 议重点关注机器人产业中价值最厚、格局最清、确定性最高环节，因为业绩弹性最大，同时我们认为龙 头在产业趋势投资阶段最为核心，因此我们建议积极寻找机器人细分环节中非标、技术、成本、扩产壁 垒高的龙头企业，因为这类企业能够穿越产业周期。整体上，我们认为机器人公司本身（软硬一体的平 台型企业）、高算力SOC芯片（大脑端侧驱动）、灵巧手（软硬件一体的小机器人）、执行器、精密传 感器（软硬件一体）等环节属于人形机器人产业高价值、高壁垒环节。 ...

Core Viewpoint - The performance of listed securities firms in 2025 is expected to show significant growth, with all 16 firms that have disclosed their earnings forecasts reporting positive results, driven by a recovery in the capital market and increased business activities in wealth management, asset management, and investment trading [1][5]. Group 1: Earnings Forecasts - Zhongtai Securities expects a net profit of 1.312 billion to 1.5 billion yuan for 2025, an increase of 40% to 60% year-on-year, attributed to a rebound in market activity and growth in various business segments [2]. - Huazhong Securities reported a total revenue of 5.064 billion yuan for 2025, a year-on-year increase of 30.94%, with a net profit of 2.104 billion yuan, up 41.64%, due to enhanced core business efforts and market opportunities [3]. - Guosheng Securities anticipates a net profit of 210 million to 280 million yuan for 2025, reflecting a year-on-year growth of 25.44% to 67.25%, driven by increased revenues in brokerage, investment banking, and futures brokerage [4]. - Founder Securities forecasts a net profit of 3.86 billion to 4.08 billion yuan, representing a year-on-year increase of 75% to 85%, primarily due to growth in wealth management and subsidiary business revenues [4]. Group 2: Major Firms' Performance - CITIC Securities reported a net profit of 30.051 billion yuan for the previous year, a year-on-year increase of 38.46%, maintaining steady growth despite a high base [6]. - Guotai Junan is expected to achieve a net profit of 27.533 billion to 28.006 billion yuan for 2025, with a year-on-year increase of 111% to 115%, attributed to brand advantages and improved service systems post-merger [6]. - China Merchants Securities reported a net profit of 12.3 billion yuan, ranking third among the firms [7]. Group 3: Industry Insights - The securities industry is entering a golden period of dual recovery in valuation and performance, supported by a significant rebound in the capital market, with total trading volume exceeding 413.78 trillion yuan in 2025 [11]. - Analysts highlight three main pillars driving growth: resilience in traditional businesses, recovery in investment banking, and the transformation towards internationalization and wealth management [11]. - The current allocation of active funds in the non-bank sector remains significantly low, indicating potential for increased investment in the securities sector as market conditions improve [12].

本报记者 周尚伃 作为行业并购重组的标杆，国泰海通2025年预计实现归母净利润275.33亿元至280.06亿元，同比增长111%至115%；预计实 现归母扣非净利润210.53亿元至215.16亿元，同比增长69%至73%。业绩大幅增长的背后，2025年，国泰海通全面提升经营管理 水平，稳中求进、主动作为，平稳高效完成合并交易，有序推动整合融合，充分发挥合并后的品牌优势、规模效应和互补效 应，优化升级零售、机构、企业三大客户服务体系，以提升综合能力实现客户经营"增量扩面、提质增效"，资产规模及经营业 绩创历史新高，财富管理、机构与交易等业务收入同比显著增长，初步实现"1+1＞2"的效果。 从已披露的数据来看，2025年上市券商业绩整体向好，形成了头部券商稳中有进、重组标的爆发增长、中小券商突围发力 的多梯队协同发展格局，高质量发展成效逐步显现。 头部券商业绩稳中有进 2025年，头部券商的规模优势与综合竞争力进一步释放，业绩表现稳中有进。具体来看，中信证券全年实现营业收入748.3 亿元，同比增长28.75%；归母净利润300.51亿元，同比增长38.46%，刷新自身盈利纪录。招商证券与光大证券同样保持稳健 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002945 | 华林证券 | 18.91 | 6.54% | 64.13万 | 11.87亿 | | 600621 | 生壁股份 | 16.96 | 4.63% | 66.29万 | 11.04亿 | | 601108 | 财通证券 | 9.46 | 2.49% | 136.03万 | 12.70亿 | | 600030 | 中信证券 | 28.56 | 2.22% | 297.78万 | 83.87亿 | | 601881 | 中国银河 | 15.26 | 1.94% | 79.48万 | 11.90 乙 | | 000712 | 锦龙股份 | 12.04 | 1.78% | 19.09万 | 2.28亿 | | 601688 | 华泰证券 | 23.24 | 1.75% | 145.32万 | 33.15亿 | | 002736 | 圖信证券 | 12.79 | 1.59% | 60.85万 | 7.70亿 | | 000783 | 长江证券 ...

中国经济网北京1月29日讯 亚虹医药(688176.SH)今日收报13.15元，跌幅7.91%。目前该股股价处于 破发状态。 亚虹医药于2022年1月7日在上交所科创板上市，发行数量为1.1亿股，发行价格为22.98元/股，保荐 机构为中信证券股份有限公司，保荐代表人为杨沁、程杰。 亚虹医药上市首日开盘即破发，当日盘中最高价报20.00元，为上市以来最高价。 (责任编辑：关婧) 亚虹医药首次公开发行股票的费用总额为1.47亿元，其中中信证券获得承销费及保荐费1.30亿元。 亚虹医药的控股股东、实际控制人、董事长兼总经理是PAN KE，美国国籍。 亚虹医药首次公开发行股票募集资金总额为25.28亿元，扣除发行费用后募集资金净额为23.81亿 元。亚虹医药最终募集资金净额比原计划多3.11亿元。亚虹医药于2021年12月31日披露的招股说明书显 示，该公司拟募集资金20.70亿元，拟分别用于药品、医疗器械及配套用乳膏生产项目，新药研发项 目，营销网络建设项目，补充流动资金。 ...